Integris Medtech recalibrates proposed IPO, reducing fresh issue component from ₹925 crore to ₹600 crore
The revision reflects market volatility amid geopolitical developments, with the company prioritising debt reduction
We haven't written up this one. Hindu BusinessLine has the full story — the link below goes straight to it.